Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application

  • Post published:September 14, 2023
  • Post category:News
Read more about the article Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

  • Post published:January 5, 2023
  • Post category:Announcements
Read more about the article MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

  • Post published:November 17, 2022
  • Post category:News/Press Release
Read more about the article Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

  • Post published:December 2, 2020
  • Post category:Press Release
Read more about the article MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

  • Post published:October 27, 2020
  • Post category:Press Release
Read more about the article Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval

Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval

  • Post published:August 20, 2020
  • Post category:Press Release
Read more about the article MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m

MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m

  • Post published:June 21, 2020
  • Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More